Treatment with B20 or A2V does not affect the presence of MDSCs in Gl261 or MGG8 tumors as compared with IgG treatment. In all Gl261 panels, IgG, n = 6; B20, n = 6; A2V, n = 5. (A and B) MDSCs were defined as CD45+/CD11bpos/GR1+/CD11b+. (C) No changes in MDSC presence were seen in Gl261 tumors. In all MGG8 panels, IgG, n = 4; B20, n = 7; A2V, n = 9. (D and E) Representative MDSC gates in the MGG8 tumor model. (F) The presence of MDSCs was not changed by treatment in the MGG8 model.